Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00962598 · ClinicalTrials.gov registry record · Phase 2
The Role Of Omega-3 Fatty Acids In Adolescent Depression
A Phase 2 study of Depressive Disorder, Major, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT00962598: Completed Phase 2 study of Depressive Disorder, Major, sponsored by Icahn School of Medicine at Mount Sinai.
NCT00962598 is a Phase 2 study of Depressive Disorder, Major that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 16 participants, below the 242-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00962598, a Phase 2 study of Depressive Disorder, Major, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the effects of a 10-week Omega-3 Fatty Acid treatment phase on brain chemistry of adolescents with major depressive disorder (MDD) using proton magnetic resonance imaging.
Primary Outcome
The data reflects the ratio of Glutamine-Glutamate and water in the brain (ratio divided by 10000 for analysis purposes). Glutamate is a precursor to Glutamine, an amino acid which functions as an excitatory neurotransmitter in the human brain.
Conditions Studied
Interventions
- DRUG Omega 3 Fatty Acids
- DIETARY_SUPPLEMENT Corn oil
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2006-01 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
What the finished NCT00962598 record still lists
NCT00962598 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 242-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Depressive Disorder, Major appearing as the primary indexed condition, and to 2 interventions - of which Omega 3 Fatty Acids is the first listed.
NCT00962598 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00962598 about?
NCT00962598 is a clinical study titled "The Role Of Omega-3 Fatty Acids In Adolescent Depression". The purpose of this study is to examine the effects of a 10-week Omega-3 Fatty Acid treatment phase on brain chemistry of adolescents with major depressive disorder (MDD) using proton magnetic resonance imaging.
What is the current status of trial NCT00962598?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2006-01. Estimated completion is 2013-06.
What conditions does trial NCT00962598 study?
This clinical trial studies the following conditions: Depressive Disorder, Major.
What interventions are being tested in trial NCT00962598?
The interventions under investigation include: Omega 3 Fatty Acids (DRUG), Corn oil (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00962598?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00962598 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Major
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00962598's enrollment target sits among peer trials
16 51st of 52 higher than 2 of 52 other Depressive Disorder, Major trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depressive Disorder, Major trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
RECRUITING · Phase 2
-
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation
RECRUITING · Phase 2
-
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
RECRUITING · Phase 2
-
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
RECRUITING · Phase 2
-
Individualized Functional Connectivity Targeting in aiTBS for Depression
ACTIVE NOT RECRUITING · Phase 2
-
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia